Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

Bob Löwenberg*, Thomas Pabst, Johan Maertens, Yvette van Norden, Bart J. Biemond, Harry C. Schouten, Olivier Spertini, Edo Vellenga, Carlos Graux, Violaine Havelange, Georgine E de Greef, Okke De Weerdt, Marie-Cecile J C Legdeur, Juergen Kuball, Marinus van Marwijk Kooy, Bjorn T Gjertsen, Mojca Jongen-Lavrencic, Arjan A van de Loosdrecht, Daniëlle van Lammeren-Venema, Beata HodossyDimitri A Breems, Yves Chalandon, Jakob Passweg, Peter J M Valk, Markus G Manz, Gert J Ossenkoppele

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science